Myeloid-derived suppressor cells in cancer cachexia syndrome: A new explanation for an old problem

Journal of Parenteral and Enteral Nutrition

Volumn 32, Issue 6, 2008, Pages 651-655

  Winfield, Robert D ^a   Delano, Matthew J ^a   Pande, Kalyan ^b   Scumpia, Philip O ^a   LaFace, Drake ^b   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cytokines; Malignancy; MDSC; Myelopoiesis; Sickness syndromes; T cell; Tumor; Wasting; Weight loss

Indexed keywords

ADALIMUMAB; CHEMOKINE; CYTOKINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANOREXIA; BONE MARROW CELL; CACHEXIA; CONFERENCE PAPER; HUMAN; INNATE IMMUNITY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TUMOR GROWTH;

ACUTE-PHASE PROTEINS; ACUTE-PHASE REACTION; CACHEXIA; CYTOKINES; ENERGY METABOLISM; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; NEOPLASMS;

ANIMALIA;

EID: 54249120376     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607108325075     Document Type: Conference Paper

References (40)

1. Delano MJ, Moldawer LL The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract. 2006 ; 21: 68-81.
2. Moldawer LL, Georgieff M., Lundholm K. Interleukin 1, tumour necrosis factor-alpha (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol. 1987 ; 7: 263-274.
3. Aderka D., Fisher S., Levo Y., Holtmann H., Hahn T., Wallach D. Cachectin/tumour-necrosis-factor production by cancer patients. Lancet. 1985 ; 2: 1190.
4. Oliff A., Defeo-Jones D., Boyer M., et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 1987 ; 50: 555-563.
5. Esper DH, Harb WA The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract. 2005 ; 20: 369-376.
6. Lonnroth C., Moldawer LL, Gelin J., Kindblom L., Sherry B., Lundholm K. Tumor necrosis factor-alpha and interleukin-1 alpha production in cachectic, tumor-bearing mice. Int J Cancer. 1990 ; 46: 889-896.
7. Gelin J., Moldawer LL, Lonnroth C., Sherry B., Chizzonite R., Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 1991 ; 51: 415-421.
8. Sherry BA, Gelin J., Fong Y., et al. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 1989 ; 3: 1956-1962.
9. Kumar S., Kishimoto H., Chua HL, et al. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am J Pathol. 2003 ; 163: 2531-2541.
10. Strassmann G., Fong M., Kenney JS, Jacob CO Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992 ; 89: 1681-1684.
11. Alexander HR, Billingsley KG, Block MI, Fraker DL D-factor/ leukaemia inhibitory factor: evidence for its role as a mediator in acute and chronic inflammatory disease. Cytokine. 1994 ; 6: 589-596.
12. Billingsley KG, Fraker DL, Strassmann G., Loeser C., Fliot HM, Alexander HR Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann Surg Oncol. 1996 ; 3: 29-35.
13. Doherty GM, Alexander HR, Merino MJ, Venzon DJ, Norton JA Role of endogenous interferon gamma in murine tumor growth and tumor necrosis factor alpha antitumor efficacy. Ann Surg Oncol. 1996 ; 3: 198-203.
14. Beutler B., Cerami A. The common mediator of shock, cachexia, and tumor necrosis. Adv Immunol. 1988 ; 42: 213-231.
15. Olsen NJ, Stein CM New drugs for rheumatoid arthritis. N Engl J Med. 2004 ; 350: 2167-2179.
16. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 ; 349: 2014-2022.
17. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 ; 337: 141-147.
18. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004 ; 50: 1051-1065.
19. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 ; 337: 1029-1035.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 ; 359: 1541-1549.
21. Mitka M. Gene studies, anti-TNF therapy take Lasker honors. JAMA. 2003 ; 290: 1979-1980.
22. Breedveld FC, Han C., Bala M., et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis. 2005 ; 64: 52-55.
23. Metsios GS, Stavropoulos-Kalinoglou A., Douglas KM, et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford). 2007 ; 46: 1824-1827.
24. Marcora SM, Chester KR, Mittal G., Lemmey AB, Maddison PJ Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006 ; 84: 1463-1472.
25. Anker SD, Coats AJ How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002 ; 86: 123-130.
26. Keane J., Gershon S., Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 ; 345: 1098-1104.
27. Kesteman T., Yombi JC, Gigi J., Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol. 2007 ; 26: 2173-2175.
28. Kusmartsev S., Cheng F., Yu B., et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003 ; 63: 4441-4449.
29. Nagaraj S., Gupta K., Pisarev V., et al. Altered recognition of antigen is a mechanism of CD8(+) T cell tolerance in cancer. Nat Med. 2007 ; 13: 828-835.
30. Kusmartsev S., Gabrilovich DI Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother. 2006 ; 55: 237-245.
31. Marx J. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science. 2008 ; 319: 154-156.
32. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007 ; 204: 1463-1474.
33. Grossie VB Jr. Influence of the ward colon tumor on the innate and endotoxin-induced inflammatory response of the rat. Cancer Invest. 2001 ; 19: 698-705.
34. Grossie VB Jr Mailman, D. Influence of the Ward colon tumor on the host response to endotoxin. J Cancer Res Clin Oncol. 1997 ; 123: 189-194.
35. Popovic PJ, Zeh HJ 3rd, Ochoa JB Arginine and immunity. J Nutr. 2007 ; 137 (6 Suppl 2). 1681S - 1686S.
36. Rodriguez PC, Ochoa AC Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008 ; 222: 180-191.
37. Makarenkova VP, Bansal V., Matta BM, Perez LA, Ochoa JB CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol. 2006 ; 176: 2085-2094.
38. Sinha P., Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005 ; 174: 636-645.
39. Tisdale MJ Cachexia in cancer patients. Nat Rev Cancer. 2002 ; 2: 862-871.
40. Nefedova Y., Fishman M., Sherman S., Wang X., Beg AA, Gabrilovich DI Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007 ; 67: 11021-11028.